James Bonnar

James Bonnar

Nyrada CEO

BSc (Chemistry), MRQA

James joined Nyrada, Inc. in February 2018 and brings over 20 years of global experience in the Life Sciences industry, including pre-clinical research, operations management, CMC (Chemistry, Manufacturing and Controls), Regulatory Affairs, and Quality Assurance. Before joining Nyrada, James was at Neuren for eleven years. During this period, he was the Director, CMC and Regulatory Affairs and then Director, Clinical Operations where he oversaw clinical development for drugs in the areas of traumatic brain injury and neurodevelopmental disorders. Prior to that he worked in diabetes research, GMP manufacturing, and drug formulation development.

James brings an experienced scientific focus to Nyrada, having led teams from early stage development through to end of Phase II.

Benny Evison

Benny Evison Ph.D

Chief Scientific Officer

B. Sc. (Med. Sci.) (Hons); PhD

Benny brings to Nyrada, Inc an expertise in advancing drug compounds from the discovery phase into clinical trials in humans. His early interest in science led him to study at La Trobe University where he obtained a Bachelor of Medical Science with Honours, followed by a PhD. His PhD involved the identification of a potential new mechanism of action of a drug called pixantrone, which is currently used for the treatment of non-Hodgkin’s lymphoma. Following his PhD, he was keen to gain more training at an international level, so he moved to Memphis, Tennessee in the USA, where he was a postdoctoral fellow at St Jude Children’s Research Hospital. His time there with very sick children was a strong motivational factor to generate important scientific research. At St Jude Children's Research Hospital, he worked on making drugs that targeted proteins involved in DNA repair to improve the activity of existing chemotherapies, before returning to Australia to become one of the first scientists at Nyrada,Inc.